ANI Pharmaceuticals had its Relative Strength (RS) Rating upgraded from 69 to 79 Monday — a welcome improvement, but still shy of the 80 or higher score you look for.
Can You Really Time The Stock Market?
IBD's unique RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks compares to other publicly traded companies.
History shows that the best stocks often have an RS Rating north of 80 in the early stages of their moves. See if ANI Pharmaceuticals can continue to rebound and clear that threshold.
ANI Pharmaceuticals is working on a consolidation with a 77.00 buy point. See if the stock can break out in volume at least 40% higher than normal.
The company showed 40% EPS growth in the latest quarterly report. Revenue gains came in at 43%.
The company holds the No. 1 rank among its peers in the Medical-Generic Drugs industry group. Dr. Reddy's Labs ADR and Collegium Pharmaceutical are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
